Trial Profile
A 12-Month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of Ranibizumab 0.5mg on cystoids, spongy and mixed Optical Coherence Tomography patterns secondary to Diabetic Macular Oedema (DME)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Novartis Healthcare
- 12 Nov 2018 New trial record